Brokerages expect Novavax, Inc. (NASDAQ:NVAX) to announce earnings of ($1.85) per share for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Novavax’s earnings, with estimates ranging from ($2.20) to ($1.50). Novavax reported earnings per share of ($2.40) in the same quarter last year, which would indicate a positive year over year growth rate of 22.9%. The business is expected to report its next quarterly earnings results on Wednesday, August 14th.
On average, analysts expect that Novavax will report full year earnings of ($6.93) per share for the current financial year, with EPS estimates ranging from ($9.20) to ($5.60). For the next fiscal year, analysts expect that the business will post earnings of ($5.41) per share, with EPS estimates ranging from ($7.20) to ($3.40). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Novavax.
Novavax (NASDAQ:NVAX) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($2.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.40) by $0.20. The business had revenue of $3.98 million for the quarter, compared to analysts’ expectations of $4.80 million. During the same quarter last year, the business posted ($2.80) earnings per share.
Shares of NVAX traded down $0.09 during mid-day trading on Friday, reaching $6.03. 4,637 shares of the company’s stock were exchanged, compared to its average volume of 1,190,992. The firm has a market cap of $148.11 million, a PE ratio of -0.61 and a beta of 2.31. Novavax has a 52-week low of $5.45 and a 52-week high of $51.60.
In other Novavax news, Director Rachel K. King bought 86,000 shares of Novavax stock in a transaction on Wednesday, March 27th. The stock was bought at an average price of $0.53 per share, with a total value of $45,580.00. Following the completion of the acquisition, the director now owns 42,000 shares in the company, valued at $22,260. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.30% of the stock is currently owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the business. DAVENPORT & Co LLC raised its stake in shares of Novavax by 400.0% during the 1st quarter. DAVENPORT & Co LLC now owns 50,000 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 40,000 shares during the last quarter. Wedbush Securities Inc. raised its stake in shares of Novavax by 102.1% during the 1st quarter. Wedbush Securities Inc. now owns 54,444 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 27,500 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Novavax by 131.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,729 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 9,515 shares during the last quarter. Great West Life Assurance Co. Can increased its position in Novavax by 79.0% during the 1st quarter. Great West Life Assurance Co. Can now owns 59,081 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 26,081 shares in the last quarter. Finally, Opti Capital Management LP purchased a new stake in Novavax during the 4th quarter worth about $39,000.
Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.
See Also: Quiet Period Expirations
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.